Navigation Links
Elekta Negotiates To Acquire CMS
Date:1/8/2008

Acquisition of leading treatment planning software developer would strengthen Elekta's offering and accelerate the company's expansion into

high growth oncology informatics

STOCKHOLM, Sweden, Jan. 8 /PRNewswire/ -- Elekta AB (publ) (STO: EKTAb) a world leader in clinical solutions for radiation therapy and radiosurgery, today announced that it is in exclusive negotiations based on a Letter of Intent to acquire CMS Inc. for a total cash consideration representing an enterprise value of USD 75 M. CMS is a worldwide leader in the development, sales and support of advanced radiation therapy planning solutions, supporting over 1,500 sites in clinical operation throughout the world. The transaction is subject to successful conclusion of final transaction documentation, satisfactory completion of due diligence, receipt of relevant regulatory approvals and other conditions. The negotiations are expected to be finalized by mid February 2008 and closing is estimated to take place by mid March 2008.

CMS has been a pioneer in the development and delivery of radiation treatment planning (RTP) systems for over 25 years and continues to be a leader in treatment planning and oncology workflow management. Successful completion of the acquisition process would benefit Elekta by adding a suite of advanced RTP systems, a large and growing installed base, and a well- established RTP operational infrastructure to Elekta's current oncology business. CMS's worldwide sales and support infrastructure and large, experienced engineering organization have the potential to accelerate Elekta's ability to develop, implement, and support new, sophisticated radiation planning, delivery, and management solutions worldwide.

CMS is also the market leader in treatment planning for proton therapy with 8 installations in clinical use. Integrating these solutions with the MOSAIQ(TM) information management system would reinforce Elekta's leadership in s
'/>"/>

SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007
2. Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse
3. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
4. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
5. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
6. Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO
7. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
8. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
9. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
10. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
11. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , October 27, 2014 ... right to produce, exhibit and sell its artificial ... to impeach their patent.      (Photo: ... four years of fighting, the definitive judgement has ... and produces innovative and accessible hi-tech prostheses with ...
(Date:10/27/2014)... The “Molecular Diagnostic Market by Application ... DNA Sequencing), End User (Hospital, Laboratories), & by ... to 2018” provides a detailed overview of the ... and strategies impacting the global molecular diagnostics market ... revenue and share analysis. , The global molecular ...
(Date:10/27/2014)... 27, 2014 The report “Smart ... Traffic Management, Communication, Monitoring), and by Display (Variable ... 2019” segments the global market into various sub-segments ... also identifies the drivers and restraints for this ... , Browse 75 market tables and 37 figures ...
(Date:10/27/2014)... October 27, 2014 Investor-Edge has ... (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ), ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,483.72, up 0.69%, the Dow Jones ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... NBIX ) today announced its financial results for the ... the fourth quarter of 2010, the Company reported net income of ... loss of $7.9 million, or $0.20 per basic share, for the ... the Company reported a net loss of $8.0 million, or $0.15 ...
... Technologies, Inc., a privately-held orthobiologics company, announced today that ... is scheduled to present at Canaccord Genuity,s Musculoskeletal Conference ... February 15, 2011 at 10:00 AM (PT).  The conference, ... Meeting, will feature presentations from over 60 public and ...
... Mass., Feb. 10, 2011 Qteros, Inc., ... Bioprocessing (CBP) platform for the lowest-cost production ... engagements across the United States and Europe for members ... Qteros, Senior Vice President, Commercial Development and Engineering, will ...
Cached Biology Technology:Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 2Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 3Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 4Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 5Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 6Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 7ISTO Technologies, Inc. to Present at Canaccord Genuity's Musculoskeletal Conference 2Qteros Management to Present at Notable Alternative Energy Conferences in February 2
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... Hebei, China — BGI Tech and Hebei Agricultural University ... Jujube genome. Jujube is the most economically important member ... particularly difficult to sequence due the high level of ... time that a genome in the Rhamnaceae (Buckthorn) family ... in Nature Communications . , Jujube ...
(Date:10/28/2014)... the tragic realities of cancer is that the ... and their effectiveness varies unpredictably from patient to ... to change this reality by rapidly assessing how ... individual,s cancer before chemotherapy begins. , A team ... Assistant Professor Melissa Skala has developed the technique, ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... A new computer model of the Gulf of Mexico ... how underwater currents may have primed marine microorganisms to degrade ... of water move over the ruptured well, picking up hydrocarbons. ... over the well, the bacteria have already been activated, are ...
... Species pairs that disappear through hybridization after ... the disturbance is removed, according to a new ... reemergence might happen. The findings, published in ... conservationists and ecosystem managers interested in preserving, or ...
... Foundation for Biodiversity, the Charter Provincial Council of Gipuzkoa and ... be studying the re-stocking of the three eel phases (elver, ... and July, respectively, in three streams of the Oria basin. ... be able to manage the species and thus contribute to ...
Cached Biology News:Gulf currents primed bacteria to degrade oil spill 2Species reemergence after collapse: Possible but different 2A study will enable the survival and growth of the 3 development phases of the European eel 2
... The ProteoExtract™ Protein Precipitation Kit ... up of proteins from aqueous samples. ... by the presence of non-protein impurities ... in the protein sample that interfere ...
... activated carrier proteins to simplify the ... Activated Carrier Proteins are commonly used ... a heterobifunctional cross-linker (Sulfo-SMCC). This activation ... protein. Thus allowing the maleimide-activated ...
... This kit allows for rapid, convenient, ... The simple bind/wash/elute process utilizes a spin ... uses beads for concentration of proteins which ... beads are strong ion exchangers, offering high ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Biology Products: